Decision to list a range of medical devices used in the prevention of venous thromboembolisms (VTE Prevention) supplied by Mӧlnlycke Health Care Pty Limited

Hospital devices

Decision

We’re pleased to announce the approval of a listing agreement with Mölnlycke Health Care Pty Limited (“Mölnlycke”) for the supply of medical devices used in the prevention of venous thromboembolisms (“VTE Prevention”) to DHB Hospitals.

What we are doing

We’re pleased to announce the approval of a listing agreement with Mӧlnlycke Health Care Pty Limited (“Mӧlnlycke”) for the supply of medical devices used in the prevention of venous thromboembolisms (“VTE Prevention”) to DHB Hospitals.

In summary this will result in:

  • Mӧlnlycke’s VTE Prevention products being listed on the Pharmaceutical Schedule from 1 May 2018 under a national agreement that all DHBs may purchase under (“Agreement”).
  • DHBs continuing to be able to purchase other suppliers’ brands of VTE Prevention products as the Agreement is not for sole supply.
  • Pricing for products in the Agreement, subject to any termination of the Agreement, would not increase prior to 1 May 2021.

Any changes to the original proposal?

This decision was subject to a consultation letter dated 8 March 2018(external link). No changes have been made to the Agreement as a result of consultation.

Who we think will be most interested

  • Suppliers and wholesalers
  • DHB staff
    • Clinicians
    • Procurement Officers

Details about this decision

In 2016 PHARMAC issued a Request for Proposals (RFP) for VTE Prevention products. The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

After completing the RFP evaluation process and consulting on the provisional Agreement reached with Mӧlnlycke, PHARMAC has decided to list Mӧlnlycke’s range of VTE Prevention products in Part III of Section H of the Pharmaceutical Schedule from 1 May 2018.

The list of products will be available on PHARMAC's website from 1 May 2018, in both a PDF document and an Excel spreadsheet.

DHBs that purchase Mӧlnlycke’s VTE Prevention products must do so under the terms and conditions, and at the prices, included in the Agreement, from 1 May 2018.

DHBs can continue to choose which VTE Prevention products they purchase.

The Agreement includes terms and conditions for training and education to be provided by Mӧlnlycke, on the appropriate use of their medical devices, which is to be provided at times as agreed with individual DHBs.

Mӧlnlycke’s VTE Prevention products are the latest that PHARMAC has decided to list on the Pharmaceutical Schedule. Further consultations in this category is expected over the next few months.

Our response to what you told us

We appreciate the time people took to consider to this consultation.

All consultation responses received by 28 March 2018 were considered in their entirety in making a decision to approve Mӧlnlycke’s provisional Agreement.

A summary of the main themes raised in feedback and our responses to the feedback received are set out below: 

Theme Comment
Feedback that no technical or resource impacts are expected as a result of the proposal. Noted.

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.